A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer

Japanese Journal of Clinical Oncology

Volumn 36, Issue 3, 2006, Pages 159-165

  Kosuge, Tomoo ^a   Kiuchi, Takahiro ^b   Mukai, Kiyoshi ^c   Kakizoe, Tadao ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Adjuvant; Chemotherapy; Clinical trials; Pancreatic neoplasms

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; PANCREAS CANCER; PANCREAS DUCT; PANCREAS RESECTION; POSTOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; SURVIVAL RATE;

EID: 33645858256     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi234     Document Type: Article

References (19)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. The Editorial Board of the Cancer Statistics in Japan. Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan (2001). In: Cancer Statistics in Japan 2003. Tokyo: Foundation for Promotion of Cancer Research 2003;36-9 (in Japanese).
3. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995;221:133-48.
4. Yeo CJ. Pancreatic cancer: 1998 update. J Am Coll Surg 1998;187:429-42.
5. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004;28:219-30.
6. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120: 899-903.
7. Bakkevold KE, Amesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: Results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1993;5:698-703.
8. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-84.
9. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomized controlled trial. Lancet 2001;358:1576-85.
10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
11. Rothman H, Cantrell JE Jr, Lokich J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer 1991;68:264-8.
12. Rougier P, Zarba JJ, Ducreux M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-6.
13. Okusaka T, Okada S, Ishii H, et al. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol 1996;26: 215-20.
14. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 5th edn. New York: John Wiley & Sons, 1997.
15. Hermanek P, Sobin LH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumors. 4th edn. Berlin: Springer, 1992.
16. Japan Pancreatic Society. Classification of pancreatic carcinoma (1st English edition). Tokyo: Kanehara & Co, 1996.
17. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-95.
19. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000;73:212-18.